Drugs / CMA2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07062198 | Sep 2025 → Sep 2026 overdue | Alzheimer disease | ScandiBio Therapeutics AB | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMA2 | “treatment with CMA2 including N-acetyl-L-cysteine (NAC), L-carnitine-L-tartrate (LCAT), nicotinamide (niacinamide), and L-serine.” NCT07062198 ↗ |
| Route | Oral | “26 weeks of b.i.d. oral administration of either CMA2 or placebo (1:1)” NCT07062198 ↗ |